Evolus Inc

Evolus Inc is a performance beauty company specializing in medical aesthetics and injectable products for the cash-pay aesthetics market. The company operates a portfolio of aesthetic consumer brands focused on facial rejuvenation and wrinkle reduction. Evolus markets two primary product lines: Jeuveau®, a proprietary botulinum toxin neurotoxin indicated for temporary improvement of moderate to severe frown lines in adults, and Evolysse, an advanced injectable hyaluronic acid formulation utilizing Cold-X™ Technology designed to soften dynamic facial wrinkles, particularly in nasolabial fold areas. Jeuveau has achieved four consecutive years as the fastest-growing neurotoxin in the U.S. market. Evolysse represents the first major advance in hyaluronic acid injectable technology launched in a decade and is FDA-approved. The company has transitioned away from traditional insurance reimbursement models, instead partnering directly with aesthetic practices to provide value-based solutions. Evolus operates a co-branded patient loyalty program called Evolus Rewards, which has enrolled over one million consumers and provides treatment incentives ($40 off per eligible treatment, once every 90 days). The program is designed to help practices drive patient retention and practice growth. Company infrastructure includes a healthcare provider portal (myevolus.evolus.com) and investor relations capabilities, indicating institutional-level operations and market presence.